Cytokine treatment may improve the efficacy of NK cell-based immunotherapies by facilitating the interactions between NK cells and tumor cells through the upregulation of ICAM-1 and enhancing the NK cell-mediated apoptosis of tumor cells through the upregulation of death receptors such as FAS and TRAIL-R2. This evidence concerns the gene ICAM1 and neoplasm.